


## Rizatriptan benzoate

<b>Cat. No.:</b>	HY-B0206		
<b>CAS No.:</b>	145202-66-0		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>25</sub> N <sub>5</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	391.47		
<b>Target:</b>	5-HT Receptor		
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 50 mg/mL (127.72 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.5545 mL	12.7724 mL	25.5447 mL
	5 mM	0.5109 mL	2.5545 mL	5.1089 mL
	10 mM	0.2554 mL	1.2772 mL	2.5545 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Rizatriptan Benzoate(Maxalt) is a 5-HT<sub>1</sub> agonist triptan drug for the treatment of migraine headaches. Target: 5-HT<sub>1</sub> agonist Rizatriptan Benzoate(Maxalt) is a 5-HT<sub>1</sub> agonist triptan drug for the treatment of migraine headaches. It is believed to work by narrowing the blood vessels around the brain. Rizatriptan also reduces the substances in the body, which can also reduce headache pain, nausea, sensitivity to light and sound and other migraine symptoms. Rizatriptan was rapidly absorbed with a median t<sub>max</sub> of 1.3 h (range 1-3 h) vs a t<sub>max</sub> for sumatriptan of 2.5 h (range 1-4 h, P < 0.001). Administration of either rizatriptan or sumatriptan produced maximal mean elevations of 5-10 mmHg in systolic and diastolic blood pressures without effect on heart rate; the changes occurred sooner following rizatriptan, consistent with more rapid absorption. Both

---

rizatriptan and sumatriptan provoked mild increases in serum growth hormone without any effect on serum prolactin concentrations. The most commonly reported symptom following rizatriptan was drowsiness.

IC<sub>50</sub> & Target

5-HT<sub>1</sub> Receptor

## REFERENCES

---

[1]. Sciberras DG, et al. Initial human experience with MK-462 (rizatriptan): a novel 5-HT<sub>1D</sub> agonist. Br J Clin Pharmacol. 1997 Jan;43(1):49-54.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA